Abstract

Introduction: According to our research, liposomes loaded with imatinib mesylate were formulated using a rotary evaporator and the thin film hydration method. FTIR, DSC, and XRD studies were carried out to ensure that the drug excipients in the final formulation were compatible.

Method: The improved liposome batch (F7) was tested for particle size (353.9 nm), zeta potential (-46.0 mV), drug release (92.8%), and entrapment efficiency (94.29%) after 72 hours. Studies using TEM have shown that imatinib mesylate-loaded liposomes have a spherical form.

Result: Finally, in-vitro anticancer activity was assessed through the MTT assay, which revealed an IC₅₀ value of 0.2959μg mL^-1 for treating Human leukaemia monocytic cell lines.

Conclusion: The process was refined based on data concerning the rotary evaporator speed, solvent system ratio and volume, hydration media pH, manufacturing yield, entrapment efficiency, in-vitro release, and improved in vitro anti-cancer activity.

Keywords: Anti-cancer, liposomes, in-vitro cytotoxicity, drug delivery, stability study, imatinib mesylate, FTIR.